Pharmacodynamic evaluation of a new insulinotropic agent rExendin-4 in vivo

Objective To identify the pharmacodynamics of a new genetic engineering peptide,rExendin-4,in normal ICR mice.Methods In normal ICR mice,observe rExendin-4's effects on blood glucose and serum insulin level,as well as blood glucose fluctuation after oral glucose load.Results The rExendin-4 shows benefitial blood glucose normalization,which dependents on the higher blood glucose stimulation and without hypoglycemia induced by insulin.It means to be a new insulinotropic agent.Conclusion The rExendin-4 can effectively and safely achieve the ideal therapy target for type 2 diabetes mellitus with much less side effects such as hypoglycemia and weight gain,and possess favorable application perspective.